Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.38 |
| ▸ | CNR2 | P34972 | 5/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31269247 | 0.94 | PIK3CD (0.34) | CNR1CNR2PIK3CDGRM5LMNA | |
| SCHEMBL31269264 | 0.94 | ABL1 (0.35) | CNR1CNR2PIK3CDGRM5 | |
| SCHEMBL31268853 | 0.93 | PDE4B (0.35) | CNR1CNR2PIK3CDPDE4BGRM5 | |
| SCHEMBL31268823 | 0.93 | ABL1 (0.38) | CNR1CNR2PIK3CD | |
| SCHEMBL31269478 | 0.91 | SYK (0.36) | PIK3CD | |
| SCHEMBL31269475 | 0.90 | PIK3CD (0.37) | PIK3CD | |
| SCHEMBL31268954 | 0.90 | PIK3CD (0.35) | PIK3CD | |
| SCHEMBL31268793 | 0.90 | PIK3CD (0.35) | CNR1CNR2PIK3CD | |
| SCHEMBL31269058 | 0.90 | PIK3CD (0.36) | CNR1CNR2PIK3CD | |
| SCHEMBL31269318 | 0.89 | PIK3CD (0.38) | CNR1CNR2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |